Experimental drug targets rogue immune cells in rare diseases
NCT ID NCT01842386
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 30 times
Summary
This early-phase study tested whether rituximab, a drug that targets certain white blood cells, is safe for people with rare diseases where the body's immune system attacks its own proteins. Seven adults with conditions like pulmonary alveolar proteinosis or severe candidiasis received the drug over six months and were followed for 18 more. The main goal was to check safety and tolerability, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ALVEOLAR PROTEINOSIS (PAP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.